Advancing science for healthier outcomes
We focus on harnessing immune science to develop novel medicines for patients.
Our Pipeline
Nektar is pioneering novel therapies for autoimmune disease and chronic inflammation designed to improve patient health by resolving disease-driving imbalances in the immune system.
We have a number of clinical trials ongoing to evaluate our investigational medicines for different disease conditions. Please follow the links below for more information on each trial, including enrollment criteria and study locations.
Clinical Trials
Atopic Dermatitis
Atopic dermatitis is a chronic inflammatory condition commonly known as eczema that causes inflammation, redness and irritation of the skin. We are exploring new therapeutic options for this condition, which can severely impact a patient’s quality of life. We hope to address these unmet needs in atopic dermatitis by aiming for long-term disease control and a reduction in the frequency of medication.
- Phase: Phase 2b
- Intervention: Rezpegaldesleukin
- Trial name: REZOLVE-AD
- Status: Active, not recruiting
Alopecia Areata
Alopecia areata is a condition that occurs when the immune system attacks hair follicles and causes hair loss. We are exploring new therapeutic options for this condition, where many patients are no longer responsive to available therapies, and long-term use of these therapies may come with unfavorable side effects.
- Phase: Phase 2b
- Intervention: Rezpegaldesleukin
- Trial name: REZOLVE-AA
- Status: Active, not recruiting
Interested in learning more about our clinical trials?
Our Medical Affairs department is here to help. Connect with us for more information about our clinical trials.
Expanded access
Nektar is committed to bringing new medicines to patients with debilitating diseases. As part of that commitment, Nektar conducts, alone or with our partners, clinical trials of our investigational medicines to demonstrate their safety and effectiveness for patients.
The data generated from these clinical trials are integral to obtaining regulatory approval of our medicines and represent the best and most efficient way to make them widely available to patients. Thus, whenever possible, Nektar will refer an individual requesting access to our investigational medicines to an appropriate clinical trial. Clinical trials enable rigorous systematic evaluation of an investigational medicine and allow for close monitoring of enrolled patients.
Making decisions for expanded access to our investigational medicines is always complex. Nektar endeavors to make ethical and fair decisions, taking into consideration the particulars of each patient’s case, the available medical and scientific information, and the probability and timing of a regulatory approval. A top priority is always ensuring that Nektar is not putting any patient at risk for unnecessary harm.
If a request for expanded access to an investigational medicine originates from a country in which Nektar has partnered with another company, the request for expanded access should be originated by a licensed physician on behalf of the patient and directed to the Nektar-partnered company.
Otherwise, a request for expanded access to a Nektar investigational medicine must originate directly from a licensed physician on behalf of the patient and should be forwarded to Nektar at [email protected]. The requesting physician must agree to obtain appropriate regulatory and ethics committee approvals, as applicable, and to comply with all other safety, monitoring, reporting, and patient consent requirements defined by Nektar.